Matthew A. Spear - 11 Jun 2021 Form 4 Insider Report for Poseida Therapeutics, Inc.

Signature
/s/ Johanna Mylet, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
11 Jun 2021
Net transactions value
-$32,459
Form type
4
Filing time
14 Jun 2021, 18:18:31 UTC
Next filing
21 Jun 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Options Exercise $5,288 +4,000 +24% $1.32 20,485 11 Jun 2021 Direct
transaction PSTX Common Stock Sale $37,747 -4,000 -20% $9.44 16,485 11 Jun 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Stock Option (Right to Buy) Options Exercise $0 -4,000 -3.2% $0.000000 119,861 11 Jun 2021 Common Stock 4,000 $1.32 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.55 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock option is fully vested and exercisable.